Related Experiment Video
Updated: Jan 22, 2026

Nitropeptide Profiling and Identification Illustrated by Angiotensin II
Published on: June 16, 2019
Natural products against renin-angiotensin system for antifibrosis therapy
Tian Yang1, Yuan-Yuan Chen1, Jing-Ru Liu1
1Faculty of Life Science & Medicine, Northwest University, No. 229 Taibai North Road, Xi'an, Shaanxi, 710069, China.
Abstract:
Fibrosis is a final pathological feature of many chronic diseases, but few interventions are available that specifically target the pathogenesis of fibrosis. The highlights of common cellular and molecular mechanisms of fibrosis facilitate the discovery of effective antifibrotic drugs. The renin-angiotensin system (RAS) plays a central physiological role in the control of blood pressure and fluid homeostasis. Emerging evidence has revealed that activation of RAS was consistently found in fibrotic tissue. At the same time, as more components of the RAS are described, other pot Potential therapeutic targets emerge, so it seems sensible to revisit the contribution of RAS in anti-fibrotic therapy. So far, angiotensin converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) are the main commercial available drugs for intervening RAS. However, RAS inhibitors had lots of limitations in long-term application owing to occurring AngII and aldosterone escape. Over the past decades, natural products have aroused growing attention as potential RAS inhibitors due to their high efficacy and low risk of side effects. In this review, we revisit the contribution of RAS and its new members to anti-fibrotic therapy. Ultimately, we summarize and evaluate the use of natural products including isolated compounds, crude extracts and traditional Chinese herbal formulas to regulate RAS. These natural products can retard tissue fibrosis by targeting different RAS components, which provide us new therapeutic strategies to discover anti-fibrotic drugs.
Insights
Natural products show promise for treating fibrosis by targeting the renin-angiotensin system (RAS). These agents offer a safer alternative to traditional RAS inhibitors, providing new therapeutic strategies for fibrotic diseases.
Area of Science:
- Pharmacology
- Pathology
- Natural Products
Background:
- Fibrosis is a common pathological outcome in chronic diseases with limited treatment options.
- The renin-angiotensin system (RAS) is implicated in fibrotic processes and blood pressure regulation.
- Current RAS inhibitors (ACEI, ARB) have limitations like AngII and aldosterone escape.
Purpose of the Study:
- To review the role of the RAS and its components in anti-fibrotic therapy.
- To explore natural products as potential modulators of the RAS for treating fibrosis.
- To evaluate natural products for their efficacy in targeting RAS in fibrotic diseases.
Main Methods:
- Literature review focusing on RAS components and fibrotic mechanisms.
- Analysis of studies on natural products (isolated compounds, extracts, herbal formulas) regulating RAS.
- Evaluation of natural products' potential to inhibit fibrosis via RAS modulation.
Main Results:
- Activation of RAS is consistently observed in fibrotic tissues.
- Natural products demonstrate potential as effective and safe RAS inhibitors.
- Various natural products can target different RAS components to retard tissue fibrosis.
Conclusions:
- The RAS presents viable therapeutic targets for anti-fibrotic strategies.
- Natural products offer promising avenues for developing novel antifibrotic drugs by modulating the RAS.
- Further research into natural products could lead to new treatments for fibrotic conditions.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
What is Natural Selection?
Antihypertensive Drugs: Direct Renin Inhibitors
Nature and Nurture
Hormonal Regulation
Antihypertensive Drugs: Angiotensin II Receptor Blockers

